The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

Imatinib, the first tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia
(CML), improves overall survival (OS), but the introduction of newer TKIs requires the …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

In patients with chronic myeloid leukemia (CML), first-line imatinib treatment leads to 8-year
overall survival (OS) probabilities above 80%. Many patients die of reasons unrelated to …

BACKGROUND Outcomes in patients with chronic myeloid leukemia in blast phase (CML‐
BP) are historically dismal. Herein, the authors sought to analyze the characteristics …

New insights have emerged from maturing long-term academic and commercial clinical
trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of …

There are different BCR-ABL1 fusion genes that are translated into proteins that are different
from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …

Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …

Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is a neoplastic
hematologic disorder, which is a functionally curable chronic disease via using tyrosine …